DexCom (NASDAQ:DXCM) Upgraded by Robert W. Baird to Outperform Rating

Robert W. Baird upgraded shares of DexCom (NASDAQ:DXCM) from a neutral rating to an outperform rating in a research report report published on Thursday morning, Marketbeat.com reports. They currently have $104.00 target price on the medical device company’s stock, up from their prior target price of $86.00.

A number of other analysts also recently weighed in on DXCM. Sanford C. Bernstein boosted their target price on shares of DexCom from $82.00 to $86.00 and gave the stock an “outperform” rating in a report on Friday, October 25th. StockNews.com downgraded shares of DexCom from a “buy” rating to a “hold” rating in a report on Saturday, November 2nd. Oppenheimer cut their price target on shares of DexCom from $115.00 to $105.00 and set an “outperform” rating on the stock in a report on Friday, October 25th. Royal Bank of Canada cut their price target on shares of DexCom from $120.00 to $115.00 and set an “outperform” rating on the stock in a report on Friday, October 25th. Finally, Wells Fargo & Company upped their price target on shares of DexCom from $90.00 to $94.00 and gave the company an “overweight” rating in a report on Wednesday, December 11th. Six research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, DexCom has a consensus rating of “Moderate Buy” and a consensus price target of $99.29.

DexCom Stock Performance

DexCom stock opened at $84.84 on Thursday. The company’s 50-day moving average price is $77.89 and its 200-day moving average price is $78.41. DexCom has a twelve month low of $62.34 and a twelve month high of $142.00. The company has a quick ratio of 2.12, a current ratio of 2.46 and a debt-to-equity ratio of 1.23. The company has a market cap of $33.14 billion, a PE ratio of 50.80, a price-to-earnings-growth ratio of 2.00 and a beta of 1.12.

Insiders Place Their Bets

In other news, EVP Sadie Stern sold 4,259 shares of the company’s stock in a transaction that occurred on Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total value of $318,275.07. Following the completion of the sale, the executive vice president now owns 71,192 shares of the company’s stock, valued at approximately $5,320,178.16. This represents a 5.64 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.30% of the company’s stock.

Institutional Investors Weigh In On DexCom

Hedge funds have recently modified their holdings of the business. Versant Capital Management Inc purchased a new stake in shares of DexCom in the 4th quarter worth approximately $25,000. Riverview Trust Co lifted its position in shares of DexCom by 100.4% in the 3rd quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock worth $31,000 after purchasing an additional 232 shares during the period. MassMutual Private Wealth & Trust FSB lifted its position in shares of DexCom by 46.7% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 833 shares of the medical device company’s stock worth $65,000 after purchasing an additional 265 shares during the period. RPg Family Wealth Advisory LLC purchased a new stake in shares of DexCom in the 3rd quarter worth approximately $57,000. Finally, Covestor Ltd lifted its position in shares of DexCom by 53.7% in the 3rd quarter. Covestor Ltd now owns 959 shares of the medical device company’s stock worth $64,000 after purchasing an additional 335 shares during the period. Hedge funds and other institutional investors own 97.75% of the company’s stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.